Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

2.
3.
4.

Relationship of electrocardiographic left ventricular hypertrophy to mortality and cardiovascular morbidity in high-risk patients.

Lonn E, Mathew J, Pogue J, Johnstone D, Danisa K, Bosch J, Baird M, Dagenais G, Sleight P, Yusuf S; Heart Outcomes Prevention Evaluation Study Investigators.

Eur J Cardiovasc Prev Rehabil. 2003 Dec;10(6):420-8.

PMID:
14671464
6.

Prognostic implications of baseline electrocardiographic features and their serial changes in subjects with left ventricular hypertrophy.

Levy D, Salomon M, D'Agostino RB, Belanger AJ, Kannel WB.

Circulation. 1994 Oct;90(4):1786-93.

PMID:
7923663
8.

Electrocardiographic criteria of left ventricular hypertrophy in general population.

Casiglia E, Schiavon L, Tikhonoff V, Bascelli A, Martini B, Mazza A, Caffi S, D'Este D, Bagato F, Bolzon M, Guidotti F, Haxhi Nasto H, Saugo M, Guglielmi F, Pessina AC.

Eur J Epidemiol. 2008;23(4):261-71. doi: 10.1007/s10654-008-9234-6. Epub 2008 Mar 6.

PMID:
18322806
9.

Regression of electrocardiographic left ventricular hypertrophy is associated with less hospitalization for heart failure in hypertensive patients.

Okin PM, Devereux RB, Harris KE, Jern S, Kjeldsen SE, Julius S, Edelman JM, Dahlöf B; LIFE Study Investigators.

Ann Intern Med. 2007 Sep 4;147(5):311-9.

PMID:
17785486
10.

Impact of incident diabetes and incident nonfatal cardiovascular disease on 18-year mortality: the multiple risk factor intervention trial experience.

Eberly LE, Cohen JD, Prineas R, Yang L; Intervention Trial Research group.

Diabetes Care. 2003 Mar;26(3):848-54.

PMID:
12610048
11.

Prognostic value of changes in the electrocardiographic strain pattern during antihypertensive treatment: the Losartan Intervention for End-Point Reduction in Hypertension Study (LIFE).

Okin PM, Oikarinen L, Viitasalo M, Toivonen L, Kjeldsen SE, Nieminen MS, Edelman JM, Dahlöf B, Devereux RB; LIFE Study Investigators.

Circulation. 2009 Apr 14;119(14):1883-91. doi: 10.1161/CIRCULATIONAHA.108.812313. Epub 2009 Mar 30.

12.

Electrocardiographic left ventricular hypertrophy and effects of antihypertensive drug therapy in hypertensive participants in the Multiple Risk Factor Intervention Trial.

MacMahon S, Collins G, Rautaharju P, Cutler J, Neaton J, Prineas R, Crow R, Stamler J.

Am J Cardiol. 1989 Jan 15;63(3):202-10.

PMID:
2521269
13.

Hypertrophy at ECG and its regression during treatment survey (HEART survey). Rationale, design and baseline characteristics of patients.

Verdecchia P, Sleight P, Avanzini F, de Simone G, Pede S, Perticone F, Schillaci G, Vanuzzo D, Angeli F, Reboldi GP, Maggioni AP.

Ital Heart J. 2003 Jul;4(7):479-83.

PMID:
14558300
14.

Prognostic value of electrocardiographic criteria for left ventricular hypertrophy.

Hsieh BP, Pham MX, Froelicher VF.

Am Heart J. 2005 Jul;150(1):161-7.

PMID:
16084164
15.
16.
17.

Electrocardiographic findings and incident coronary heart disease among participants in the Atherosclerosis Risk in Communities (ARIC) study.

Machado DB, Crow RS, Boland LL, Hannan PJ, Taylor HA Jr, Folsom AR.

Am J Cardiol. 2006 Apr 15;97(8):1176-1181. Epub 2006 Mar 9.

PMID:
16616022
18.

The influence of pre-operative electrocardiographic abnormalities and cardiovascular risk factors on patient and graft survival following renal transplantation.

Woo YM, McLean D, Kavanagh D, Ward L, Aitken S, Miller GJ, Egan P, Hughes K, Clark L, Carswell K, Morris ST, Northridge DB, Rodger RS, Jardine AG.

J Nephrol. 2002 Jul-Aug;15(4):380-6.

PMID:
12243367
19.

Electrocardiographic left ventricular hypertrophy in renal transplant recipients: prognostic value and impact of blood pressure and anemia.

Rigatto C, Foley R, Jeffery J, Negrijn C, Tribula C, Parfrey P.

J Am Soc Nephrol. 2003 Feb;14(2):462-8.

20.

Ethnic differences in electrocardiographic criteria for left ventricular hypertrophy: the LIFE study. Losartan Intervention For Endpoint.

Okin PM, Wright JT, Nieminen MS, Jern S, Taylor AL, Phillips R, Papademetriou V, Clark LT, Ofili EO, Randall OS, Oikarinen L, Viitasalo M, Toivonen L, Julius S, Dahlöf B, Devereux RB.

Am J Hypertens. 2002 Aug;15(8):663-71.

PMID:
12160187

Supplemental Content

Support Center